Clinical Trial Update: Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD) [Phase 1]

View source ↗

Summary

A Phase 1 trial by GlaxoSmithKline evaluated T-cell responses to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD) in dermatitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatitis

Drugs mentioned

• Keyhole Limpet Hemocyanin (KLH) (KLH)
• Tuberculin Purified Protein Derivative (PPD) (PPD)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Dermatitis | Phase 1 | Status: COMPLETED